Posted on 04/06/2015 10:10:54 AM PDT by nickcarraway
San Diego-based Aethlon Medical Inc., a company developing targeted therapeutic devices to address infectious diseases and cancer, announced that its majority-owned subsidiary Exosome Sciences Inc. has entered into a research collaboration with Thomas Jefferson University, which is in Philadelphia.
The goal of the collaboration is to advance a "liquid biopsy" that could improve the diagnoses and monitoring of head and neck cancer. In this regard, researchers will seek to determine whether exosome-based molecular signatures correlate with and predict patient responses to therapy.
Aethlon Medicals lead product is the Aethlon Hemopurifier, a therapeutic device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences is a subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.
This is a ping list for cancer survivors and caregivers to share information. If you would like your name added to or removed from this ping list, please tell us in the comments section at this link (click here). (For the most updated list of names, click on the same link and go to the last comment.)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.